These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 1483263)
1. Lack of therapeutic effects of platelet activating factor antagonists in WEHI-3B leukemia, human xenotransplanted colorectal and lung cancer and Lewis-lung tumor in vivo. Koenigsmann M; Zafferani M; Danhauser-Riedl S; Reufi B; Houlihan WJ; Thiel E; Berdel WE Cancer Lett; 1992 Dec; 67(2-3):145-56. PubMed ID: 1483263 [TBL] [Abstract][Full Text] [Related]
2. Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines. Danhauser-Riedl S; Felix SB; Houlihan WJ; Zafferani M; Steinhauser G; Oberberg D; Kalvelage H; Busch R; Rastetter J; Berdel WE Cancer Res; 1991 Jan; 51(1):43-8. PubMed ID: 1988103 [TBL] [Abstract][Full Text] [Related]
3. Antitumoral activity of a xanthate compound. II. Therapeutic studies in murine leukemia and tumor models in vivo. Schick HD; Danhauser-Riedl S; Amtmann E; Busch R; Reichert A; Steinhauser G; Rastetter J; Sauer G; Berdel WE Cancer Lett; 1989 Jul; 46(2):149-52. PubMed ID: 2752384 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436 [TBL] [Abstract][Full Text] [Related]
5. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. Handley DA; Van Valen RG; Melden MK; Houlihan WJ; Saunders RN J Pharmacol Exp Ther; 1988 Nov; 247(2):617-23. PubMed ID: 3183958 [TBL] [Abstract][Full Text] [Related]
7. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma. Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Tressler RJ; Garvin LJ; Slate DL Int J Cancer; 1994 May; 57(4):568-73. PubMed ID: 8181860 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159 [TBL] [Abstract][Full Text] [Related]
12. Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia. Sharabani H; Izumchenko E; Wang Q; Kreinin R; Steiner M; Barvish Z; Kafka M; Sharoni Y; Levy J; Uskokovic M; Studzinski GP; Danilenko M Int J Cancer; 2006 Jun; 118(12):3012-21. PubMed ID: 16395705 [TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Dorr RT; Liddil JD; Sami SM; Remers W; Hersh EM; Alberts DS Anticancer Drugs; 2001 Mar; 12(3):213-20. PubMed ID: 11290869 [TBL] [Abstract][Full Text] [Related]
15. WEHI-3B D+ Y1 leukemia cells as a model system to assess the induction of differentiation in vivo. Gamba-Vitalo C; Carman MD; Sartorelli AC Cancer Commun; 1989; 1(3):157-65. PubMed ID: 2561737 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518 [TBL] [Abstract][Full Text] [Related]
17. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide. Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053 [TBL] [Abstract][Full Text] [Related]
18. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Brunton VG; Workman P Br J Cancer; 1993 May; 67(5):989-95. PubMed ID: 8388233 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a piperidine phospholipid. Houlihan WJ; Lee ML; Munder PG; Handley DA; Nemecek GA; Jaeggi CS; Winslow CW Arzneimittelforschung; 1994 Dec; 44(12):1384-8. PubMed ID: 7848363 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Burres NS; Clement JJ Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]